Loading data...
Loading data...
Analyzing the stock…
70
Gathering technical, fundamental, and market data — a few seconds
Technology · ·
$94.90
▲ $0.18 (+0.2%)
Market data updated: 09/19 05:08 AM
Fundamentals updated: 09/19/2026
News analyzed: 09/19/2026
Market Cap
Not available
Day Range
$92.60 - $96.26
52-Week Range
$30.08 - $96.66
Beta
—
Next Earnings
—
Support
$71.40
Resistance
$96.66
HNGE is a stock from the Technology sector — Software, hardware, chip, and computing-services companies — revenue tied to the pace of innovation and upgrade cycles.
+66.8% (1Y)
Strengths: 17/31 factors positiveRisk: Medium
This score and all analysis on this page are for informational and educational purposes only and do not constitute investment advice. Read the full disclaimer
Weighted: Technical 25% · Fundamental 20% · Growth 15% · Valuation 15% · News 10% · Quality 10% · Risk 5%
Overall Score
🟡 Mixed
Technical Trend
🟢 Bullish
Insiders
🔴 Bearish
Computed directly from the same signals behind the score above — not AI-generated.
Biggest positive driver
Revenue growth (last year)
Revenue growth (last year): 50.6%
Growth
Biggest negative driver
DCF Fair Value
Estimated fair value: $79.82 vs. price $94.90 (-15.9%)
Fair Value
What to watch next
When today echoes the past.
NO RELIABLE ECHO FOUND
Only 2 historical analog(s) found after removing overlapping dates — too few for a statistically meaningful comparison.
Historical matches considered: 2
TIME ECHO identifies historical situations that resemble the current market state. Historical outcomes are not guarantees of future performance. Similarity does not imply causation, and results may change as new data becomes available.
🗓️ What Changed This Week
🌱 Building History
We don't have a real data point from a week ago for this stock yet. The weekly comparison will appear once enough history has accumulated.
📊 Score History
60
Today
—
30D
—
90D
—
1Y
🕰️ Signal Timeline
What StockIQ actually saw for this stock, and what happened after each signal — real data, not a forecast.
3d ago · $94.79
Evidence: FOMO score jumped from 10 to 41 day-over-day
What happened after
Still awaiting outcome
🐂🐻 Investment Thesis
🐂 Bull Case
🐻 Bear Case
🔍 What Could Prove This Wrong
This isn't a price-direction forecast — just a synthesis of real, already-computed data, and future conditions that could change the picture.
🧬 STOCK DNA
This stock's profile across 8 real dimensions — a research tool, not a recommendation
Growth
54
Quality
47
Value
38
Momentum
88
Risk
56
Sentiment
100
Fundamental
35
Institutional
0
Stocks with a similar DNA right now
This stock hasn't been analyzed by StockIQAI's movement engine yet — coverage is still expanding. Check back soon.
Recent media coverage of Hinge Health, Inc. has centered on its strong financial performance and strategic growth. The company reported a 53% year-over-year revenue increase in Q2 2026, raising its full-year 2026 revenue guidance to $856–$860 million, surpassing analyst expectations. Additionally, Hinge Health expanded its clinical partnerships under the Judi Health™ brand, adding Color Health, WellTheory, and Cylinder to its ecosystem. Stock performance and executive share sales were also noted, with a director selling shares while maintaining a significant stake.
AI summary based on English-language news sources only — not investment advice.
Everyone's writing about Hinge Health, Inc.. News trend score: 100. Reason: 11 of the last 20 articles are positive, versus 0 negative.
News trend analysis is based on article sentiment only, and is not investment advice or financial counsel. Read the full disclaimer
🌡️ Emotional Temperature
42
🎯 Conviction (vs. Emotion)
38
Psychology
63
Fundamentals
35
Technical
88
Valuation
38
The price is holding at a real, documented historical support/resistance level (a 50-day high or low).
The stock is moving in lockstep with its peers at the same intensity, rather than on its own data.
Extreme momentum, price far above its moving average, and a large premium over fair value.
Price, volume, and sentiment accelerating together — a sign investors are chasing the price, not just following it.
The price rise has far outpaced the actual improvement in fundamental data.
Price (3M)
+37%
Market Narrative
74
Fundamental Reality
38
Narrative Gap
+36
🔀 Psychology Acceleration
News attention/sentiment is running well ahead of the price move itself.
🧠 StockIQ Psychologist
The market behavior suggests a dominant euphoric bias, where price momentum, extreme sentiment, and valuation above intrinsic metrics create a detached narrative from fundamentals. Overconfidence and anchoring further imply traders may ignore deteriorating earnings growth, focusing instead on short-term gains and resistance levels. The key open question is whether this disconnect will persist or if a correction will force a reassessment of the stock’s valuation. The large narrative gap (38 points) hints at a growing divergence between market perception and underlying reality.
Updated: 09/09/2026, 05:08 AM
What could change this?
👥 What the crowd believes
"Hinge Health raised its full-year 2026 revenue guidance to between $856 million and $860 million, well above consensus estimates of $822.16 million."
"Judi Health™ announces three of the newest partners to its expanding clinical programs partnership ecosystem: Color Health, WellTheory, and Cylinder."
"Hinge Health offers an app-based artificial intelligence-enabled program for managing pain and has been growing its client base as demand surges."
"Baron Small Cap Fund was up 12.57% (Institutional Shares) in the second quarter, trailing the Russell 2000 Growth Index by 13.14%."
🧠 Market Brain events driving this
📈 9D Investor Psychology
Signal classification confidence: High (confidence in the behavioral read, not a price prediction). Describes observable market behavior, not what any individual investor thinks, and is not a buy/sell signal.
🏛️ Investor DNA — Historical Investors
A Historical Strategy Simulation: assuming each investor follows their documented principles, how would they rate this stock today? This is not a prediction of what they would actually do.
🟢 Best match
Edgar Lawrence Smith — 63/100
🔴 Weakest match
Samuel Armstrong Nelson — 11/100
🗣️ Why do they disagree?
This stock sparks a sharp divide among methodologies, with scores ranging from a cautious 63—where Smith and Housel see it as a *reasonable* but not standout hold—to a resounding 12, where Veblen and Marks (Market Cycle) would dismiss it outright as either a speculative bubble or late-cycle speculation. The middle ground, from Fisher (60) down to Malkiel/Bogle (53), suggests a stock with *some* merits but lacking the exceptional quality, trend clarity, or value edge these investors prioritize. Meanwhile, the lowest scorers—Graham (28), Nelson (22), and Mackay (33)—flag red flags like overvaluation, cyclical exhaustion, or crowd-driven hype, while Lynch and Marks (41–45) note that growth may already be priced in. The contrast highlights a core tension: some see it as a *tolerable* long-term bet (Smith, Housel), while others would avoid it entirely due to perceived risk, speculative fervor, or market timing.
Edgar Lawrence Smith
Common Stocks as Long-Term Investments (1924)
🟡 63
Reasonable but not a clear long-term holding
Key question
Is this a stock I'd be happy to hold and forget about for a decade?
Fact → Principle → Simulation
Morgan Housel
The Psychology of Money (2020)
🟡 63
Moderate — holdable, but not effortless
Key question
Could I live with this volatility long enough for compounding to actually work?
Fact → Principle → Simulation
Philip Fisher
Common Stocks and Uncommon Profits (1958)
🟡 60
Solid, but not the exceptional quality Fisher looked for
Key question
How exceptional is this business, really?
Fact → Principle → Simulation
Jesse Livermore
Reminiscences of a Stock Operator (1923) / How to Trade in Stocks (1940)
🟡 59
No clear trend — Livermore preferred to stay out of this
Key question
What is the price telling me right now?
Fact → Principle → Simulation
Walter Bagehot
Lombard Street (1873)
🟡 58
Adequate but not exceptional liquidity
Key question
Does this company have enough liquidity to survive real stress?
Fact → Principle → Simulation
Burton Malkiel & John Bogle
A Random Walk Down Wall Street (1973) / The Little Book of Common Sense Investing (2007)
🟡 52
Mixed case — the evidence for picking this stock over an index is not strong
Key question
Do I actually have an edge here, or do I just think I do?
Fact → Principle → Simulation
Gerald M. Loeb
The Battle for Investment Survival (1935)
🟡 48
Moderate risk to capital
Key question
How much capital could I lose here if I'm wrong?
Fact → Principle → Simulation
Peter Lynch
One Up on Wall Street (1989)
🟡 45
Mixed — growth exists but the price already reflects much of it
Key question
Is the growth worth the price?
Fact → Principle → Simulation
Howard Marks
The Most Important Thing (2011) / Mastering the Market Cycle (2018)
🟡 40
Mixed — a good business, but expectations may already be high
Key question
What is the market probably misunderstanding about the risk here?
Fact → Principle → Simulation
Charles Mackay
Extraordinary Popular Delusions and the Madness of Crowds (1841)
🔴 33
Pattern consistent with a crowd delusion Mackay would flag
Key question
Am I being swept along with the crowd, or thinking for myself?
Fact → Principle → Simulation
Howard Marks (Market Cycle)
Mastering the Market Cycle (2018)
🔴 31
Looks late-cycle — the position Marks would treat with extra caution
Key question
Where are we in the cycle right now — near a hot extreme, or a cold one?
Fact → Principle → Simulation
Benjamin Graham (Enterprising Investor)
The Intelligent Investor (1949) — the Enterprising Investor chapters
🔴 30
Not statistically cheap enough for the Enterprising Investor's looser safety bar
Key question
Is the stock statistically cheap enough to justify the extra risk?
⚠️ Partial data for this stock — score is less reliable — Data availability: 45%
Fact → Principle → Simulation
Jack Schwager
Market Wizards (1989)
🔴 28
No real setup here — the discipline Schwager's wizards shared would say stay out
Key question
What's the risk/reward here, and where is my exit point?
Fact → Principle → Simulation
Benjamin Graham
Security Analysis (1934) / The Intelligent Investor (1949)
🔴 27
Fails most of Graham's defensive criteria
Key question
Where is my margin of safety?
Fact → Principle → Simulation
Thorstein Veblen
The Theory of Business Enterprise (1904)
🔴 12
Pattern Veblen would flag as growth pursued for its own sake
Key question
Is management building real value, or just building itself?
Fact → Principle → Simulation
Samuel Armstrong Nelson
The ABC of Stock Speculation (1903)
🔴 11
Cycle looks stretched toward overbought
Key question
Is the price overextended, or is there still room to move?
Fact → Principle → Simulation
Based on the last 280 trading days, calculated from real price data. Click an indicator for details and a chart.
🟢 Most indicators support an uptrend (10 bullish · 1 bearish · 1 neutral)
A market-structure read based purely on real price and volume data — not full classic Wyckoff schematic identification (Phase A-E), but a quantitative analysis of what can reliably be computed: trading ranges, "effort vs. result", volume within the range, and Spring/Upthrust detection.
The stock is in a clear uptrend with no defined trading range in the period examined.
High confidence
The Wyckoff Method, developed by Richard Wyckoff in the early 20th century, reads the balance of supply and demand through price and volume, based on the premise that large investors ("smart money") quietly accumulate shares before rallies and quietly distribute them before declines. The read here is based solely on real price and volume data — full, precise identification of classic Wyckoff patterns (such as Phases A-E) requires human chart-reading experience and judgment, so this is an approximate algorithmic read, not a substitute for professional analysis. This should not be considered investment advice.
Gross Margin
79.7%
Operating Margin
-92.9%
Net Margin
-89.9%
EBITDA Margin
—
ROE
-139.5%
ROA
-70.9%
ROIC
—
EPS
-$7.77
Cash
$208.00M
Total Debt
—
Current Ratio
1.47
Debt/Equity
0.00
How is Fair Value calculated? →
Current Price
$94.90
Estimated Fair Value (DCF)
$79.82
Model estimate — not a price target. Highly sensitive to growth/discount-rate assumptions.
Gap
-15.9%
🔴 Appears expensive relative to estimated value
Year 1 Growth Rate
25.0%
Discount Rate (WACC)
9.0%
Terminal Growth Rate
2.5%
Projection Years
5
| Year | Growth Rate | Projected FCF | Present Value |
|---|---|---|---|
| 1 | 25.0% | $213.42M | $195.79M |
| 2 | 19.4% | $254.77M | $214.43M |
| 3 | 13.8% | $289.80M | $223.78M |
| 4 | 8.1% | $313.34M | $221.98M |
| 5 | 2.5% | $321.18M | $208.74M |
Base FCF (last actual year)
$170.73M
Terminal Value
$5.06B
Present Value of Terminal Value
$3.29B
Enterprise Value
$4.36B
Net Debt
$0
Equity Value
$4.36B
*The DCF model is an estimate based on assumptions — not a guaranteed forecast. You can change the assumptions to examine different scenarios.
Book Value per Share
$4.78
Tangible Book Value per Share (Tangible NAV)
$4.75
Sentiment based on basic keywords (not AI) — 11 positive, 9 neutral, 0 negative out of the last 20 articles.
Yahoo · 18.9.2026
Yahoo · 16.9.2026
Yahoo · 16.9.2026
Yahoo · 15.9.2026
MarketBeat · 15.9.2026
Benzinga · 15.9.2026
MT Newswires · 14.9.2026
Investor's Business Daily · 12.9.2026
Yahoo · 12.9.2026
Insider Monkey · 12.9.2026
Yahoo · 12.9.2026
Investor's Business Daily · 11.9.2026
Yahoo · 11.9.2026
Yahoo · 11.9.2026
Investor's Business Daily · 11.9.2026
Yahoo · 9.9.2026
Yahoo Finance · 9.9.2026
Benzinga · 8.9.2026
Yahoo · 4.9.2026
Motley Fool · 4.9.2026
Hinge Health, Inc. (HNGE) currently has a StockIQ AI score of 60/100, rated "Moderate". The score is a weighted average across up to 7 categories (technical, fundamental, growth, fair value, news, quality, risk), based on real data only.
HNGE currently scores 60/100 (Moderate) across the categories we measure. StockIQ doesn't give buy/sell recommendations — use this as one data point in your own research, not as investment advice.
Per StockIQ's DCF model, HNGE's estimated fair value is $79.82, which is 15.9% below the current price of $94.90. This is one valuation model among several signals in the fair-value category, not a price target.
HNGE's technical score is 88/100, which currently reads as bullish — based on real price/volume signals (moving averages, RSI, MACD, and more), not a prediction of what happens next.
Based on the real signals StockIQ computed: Revenue growth (last year): 50.6%; Free cash flow growth: 256.0%; Calmar: 2.09 (3y annualized return 101.3% / max drawdown 48.5%).
Based on the real signals StockIQ computed: Estimated fair value: $79.82 vs. price $94.90 (-15.9%); Operating margin: -92.9% (negative); Net margin: -89.9% (negative).
StockIQ has no recorded dividend payment history for HNGE.
Real transactions by officers and insiders, as reported to the SEC on Form 4 — 0 purchases and 18 sales out of the last 25 filings.
| Name | Transaction Type | Date | Shares | Change | Price |
|---|---|---|---|---|---|
| Robinson Elliott | Open Market Sale | 8.9.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 4.9.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 3.9.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 2.9.2026 | 0 | +0 | — |
| Budge James | Tax Withholding in Shares | 1.9.2026 | 9,986 | -9,986 | $92.56 |
| Pursley James | Tax Withholding in Shares | 1.9.2026 | 6,326 | -6,326 | $92.56 |
| Robinson Elliott | Open Market Sale | 26.8.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 26.8.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 25.8.2026 | 0 | +0 | — |
| Robinson Elliott | Open Market Sale | 25.8.2026 | 0 | +0 | — |
| Budge James | Gift | 24.8.2026 | 414,609 | -11,563 | — |
| Budge James | Gift | 24.8.2026 | 11,563 | -11,563 | — |
| Pursley James | Open Market Sale | 21.8.2026 | 709,646 | -22,789 | $88.25 |
| Pursley James | Open Market Sale | 21.8.2026 | 706,235 | -3,411 | $88.68 |
| Pursley James | Open Market Sale | 21.8.2026 | 738,735 | -500 | $84.80 |
| Pursley James | Open Market Sale | 21.8.2026 | 732,435 | -6,300 | $87.23 |
| Pursley James | Open Market Sale | 21.8.2026 | 500 | -500 | $84.80 |
| Pursley James | Open Market Sale | 21.8.2026 | 6,300 | -6,300 | $87.23 |
| Pursley James | Open Market Sale | 21.8.2026 | 3,411 | -3,411 | $88.68 |
| Pursley James | Open Market Sale | 21.8.2026 | 22,789 | -22,789 | $88.25 |
| Leslie Kristina M | Open Market Sale | 20.8.2026 | 1,200 | -1,200 | $88.23 |
| Robinson Elliott | Open Market Sale | 19.8.2026 | 0 | +0 | — |
| Wardi Teddie Benjamin | Other Transaction | 10.8.2026 | 4,637 | +4,637 | — |
| Wardi Teddie Benjamin | Other Transaction | 10.8.2026 | 4,637 | +4,637 | — |
| Mecklenburg Gabriel M.I. | Tax Withholding in Shares | 4.8.2026 | 509,423 | -509,423 | $77.65 |
Official FINRA data — the number of shares open in short positions, plus daily short-sale activity.
5,439,387 shares short as of 2026-08-31 · vs. 5,963,731 on 2026-07-31
Official biweekly report (FINRA Rule 4560) — no real higher-frequency data exists for this metric.
50.8% of trading volume this week was short selling, vs. 45.8% the prior week
Based on daily short-sale volume (Reg SHO) — a different metric from the open short interest above: this is daily trading volume, not an open position, so it updates weekly rather than biweekly.
Full breakdown of every data type and its source: Data Sources · Methodology